|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: USP37 |
Gene summary for USP37 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | USP37 | Gene ID | 57695 |
| Gene name | ubiquitin specific peptidase 37 | |
| Gene Alias | USP37 | |
| Cytomap | 2q35 | |
| Gene Type | protein-coding | GO ID | GO:0000082 | UniProtAcc | A0A024R416 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57695 | USP37 | CCI_1 | Human | Cervix | CC | 2.08e-02 | 4.76e-01 | 0.528 |
| 57695 | USP37 | CCI_2 | Human | Cervix | CC | 1.05e-04 | 5.55e-01 | 0.5249 |
| 57695 | USP37 | CCI_3 | Human | Cervix | CC | 7.02e-10 | 5.93e-01 | 0.516 |
| 57695 | USP37 | LZE4T | Human | Esophagus | ESCC | 1.50e-15 | 3.59e-01 | 0.0811 |
| 57695 | USP37 | LZE7T | Human | Esophagus | ESCC | 2.86e-02 | 2.79e-01 | 0.0667 |
| 57695 | USP37 | LZE8T | Human | Esophagus | ESCC | 8.71e-08 | 1.51e-01 | 0.067 |
| 57695 | USP37 | LZE24T | Human | Esophagus | ESCC | 1.39e-06 | 1.74e-01 | 0.0596 |
| 57695 | USP37 | P2T-E | Human | Esophagus | ESCC | 2.23e-22 | 3.48e-01 | 0.1177 |
| 57695 | USP37 | P4T-E | Human | Esophagus | ESCC | 6.78e-06 | 1.45e-01 | 0.1323 |
| 57695 | USP37 | P5T-E | Human | Esophagus | ESCC | 1.92e-08 | 1.62e-01 | 0.1327 |
| 57695 | USP37 | P8T-E | Human | Esophagus | ESCC | 9.23e-16 | 1.92e-01 | 0.0889 |
| 57695 | USP37 | P9T-E | Human | Esophagus | ESCC | 6.56e-11 | 1.37e-01 | 0.1131 |
| 57695 | USP37 | P10T-E | Human | Esophagus | ESCC | 2.56e-12 | 2.13e-01 | 0.116 |
| 57695 | USP37 | P11T-E | Human | Esophagus | ESCC | 3.46e-05 | 2.70e-01 | 0.1426 |
| 57695 | USP37 | P12T-E | Human | Esophagus | ESCC | 4.06e-12 | 2.83e-01 | 0.1122 |
| 57695 | USP37 | P15T-E | Human | Esophagus | ESCC | 3.58e-11 | 3.57e-01 | 0.1149 |
| 57695 | USP37 | P16T-E | Human | Esophagus | ESCC | 2.42e-13 | 2.57e-01 | 0.1153 |
| 57695 | USP37 | P20T-E | Human | Esophagus | ESCC | 1.62e-17 | 2.69e-01 | 0.1124 |
| 57695 | USP37 | P21T-E | Human | Esophagus | ESCC | 1.34e-16 | 2.11e-01 | 0.1617 |
| 57695 | USP37 | P22T-E | Human | Esophagus | ESCC | 4.61e-09 | 2.49e-01 | 0.1236 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00447725 | Cervix | CC | mitotic cell cycle phase transition | 89/2311 | 424/18723 | 2.70e-07 | 1.12e-05 | 89 |
| GO:00000824 | Cervix | CC | G1/S transition of mitotic cell cycle | 49/2311 | 214/18723 | 1.16e-05 | 2.48e-04 | 49 |
| GO:00448434 | Cervix | CC | cell cycle G1/S phase transition | 53/2311 | 241/18723 | 1.76e-05 | 3.32e-04 | 53 |
| GO:00062602 | Cervix | CC | DNA replication | 48/2311 | 260/18723 | 2.70e-03 | 1.85e-02 | 48 |
| GO:00711083 | Cervix | CC | protein K48-linked deubiquitination | 10/2311 | 35/18723 | 7.99e-03 | 4.18e-02 | 10 |
| GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
| GO:00062604 | Esophagus | ESCC | DNA replication | 181/8552 | 260/18723 | 3.55e-15 | 2.05e-13 | 181 |
| GO:000008214 | Esophagus | ESCC | G1/S transition of mitotic cell cycle | 134/8552 | 214/18723 | 4.04e-07 | 5.55e-06 | 134 |
| GO:004484314 | Esophagus | ESCC | cell cycle G1/S phase transition | 148/8552 | 241/18723 | 5.68e-07 | 7.48e-06 | 148 |
| GO:00062754 | Esophagus | ESCC | regulation of DNA replication | 73/8552 | 107/18723 | 1.97e-06 | 2.28e-05 | 73 |
| GO:007064612 | Esophagus | ESCC | protein modification by small protein removal | 95/8552 | 157/18723 | 1.25e-04 | 8.56e-04 | 95 |
| GO:00165793 | Esophagus | ESCC | protein deubiquitination | 79/8552 | 139/18723 | 5.23e-03 | 1.97e-02 | 79 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| USP37 | SNV | Missense_Mutation | c.607N>C | p.Glu203Gln | p.E203Q | Q86T82 | protein_coding | tolerated(0.15) | possibly_damaging(0.494) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD | |
| USP37 | SNV | Missense_Mutation | c.899N>C | p.Arg300Thr | p.R300T | Q86T82 | protein_coding | tolerated(0.09) | possibly_damaging(0.815) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| USP37 | SNV | Missense_Mutation | c.554N>G | p.Ser185Cys | p.S185C | Q86T82 | protein_coding | tolerated(0.06) | benign(0.343) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| USP37 | SNV | Missense_Mutation | novel | c.722N>A | p.Thr241Asn | p.T241N | Q86T82 | protein_coding | tolerated(0.51) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| USP37 | SNV | Missense_Mutation | rs542019194 | c.18N>G | p.Ile6Met | p.I6M | Q86T82 | protein_coding | tolerated(0.07) | benign(0.24) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| USP37 | SNV | Missense_Mutation | c.652N>C | p.Asp218His | p.D218H | Q86T82 | protein_coding | deleterious(0.04) | probably_damaging(0.972) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| USP37 | SNV | Missense_Mutation | novel | c.1675N>T | p.Leu559Phe | p.L559F | Q86T82 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| USP37 | insertion | Nonsense_Mutation | novel | c.2896_2897insGAC | p.Ser966delinsTer | p.S966delins* | Q86T82 | protein_coding | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| USP37 | insertion | Nonsense_Mutation | novel | c.2895_2896insCTCTTCATGTTACACTAA | p.Gln965_Ser966insLeuPheMetLeuHisTer | p.Q965_S966insLFMLH* | Q86T82 | protein_coding | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| USP37 | SNV | Missense_Mutation | c.1056N>A | p.Met352Ile | p.M352I | Q86T82 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |